Fig. 4: Comparison of immune profiles between CDH1-MT and WT GC in all cohort and MSS/MSI-H cohorts, respectively. | npj Precision Oncology

Fig. 4: Comparison of immune profiles between CDH1-MT and WT GC in all cohort and MSS/MSI-H cohorts, respectively.

From: Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer

Fig. 4

a The positivity rates of PD-L1 expression were lower in the CDH1-MT cohort, compared to the CDH1-WT cohort (CPS ≥ 1). b, c No significant difference in MSI-H and TMB status was shown between the CDH1-WT/MT cohort. d The association of CDH1 mutations with immune checkpoint inhibitor-related survival in GC patients. **p < 0.01. ***p < 0.001. NS not significant.

Back to article page